Tecovirimat

CHEMBL1257073 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
376.3 g/mol
LogP
2.6
Phase
4

Tecovirimat is an antiviral agent that inhibits the VP37 protein of orthopoxviruses, blocking the wrapping of intracellular mature virions and thereby preventing efficient spread of the virus between cells and to extracellular environments. It is approved for the treatment of smallpox and has been used under emergency authorization for mpox (monkeypox), representing a key countermeasure in orthopoxvirus preparedness. Its highly selective mechanism targets a viral protein with no human homolog, providing a favorable safety profile.

Molecular Weight

376.3000 g/mol

LogP

2.60

TPSA

66.50 Ų

Lipinski RO5

Pass

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)c1ccc(C(F)(F)F)cc1

InChI

InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+

Molecular Formula

C19H15F3N2O3

HBD / HBA

1 / 6

Rotatable Bonds

1

Heavy Atoms

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Tecovirimat is an antiviral agent that inhibits the VP37 protein of orthopoxviruses, blocking the wrapping of intracellular mature virions and thereby preventing efficient spread of the virus between cells and to extracellular environments. It is approved for the treatment of smallpox and has been used under emergency authorization for mpox (monkeypox), representing a key countermeasure in orthopoxvirus preparedness. Its highly selective mechanism targets a viral protein with no human homolog, providing a favorable safety profile.

Yes, Tecovirimat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1257073. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16124688. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.